MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
The excitement over the MGuard(TM) stent system at TCT '08 commenced onthe first day of the conference with Dr. Eberhard Grube's inspiringpresentation on MGuard(TM): "Coronary Stent Grafts and Micro Stents - TheInspireMD Woven PET Polymer MGuard(TM) Stent Graft: Clinical Experiences inSaphenous Vein Grafts and Native Coronaries". Dr. Eberhard Grube is Professorof Medicine, Chief of the Department of Cardiology and Angiology at HeliosHeart Centre in Siegburg, Germany and Consulting Professor in the Division ofCardiovascular Medicine at Stanford University School of Medicine.
On the TCT '08 exhibition floor the InspireMD booth received muchattention throughout the event and a constant stream of excited visitorsenjoyed the demonstrations of the novel MGuard(TM) coronary stent system.Interventional cardiologists eager to implement this approach in a variety oflesions and indications approached the InspireMD staff and inquired aboutdistributors in their countries in order to request the MGuard(TM) at theirlocal hospitals for ACS, AMI and SVG procedures claiming they had manypatients they could treat with the MGuard(TM) stent system.
On Wednesday, October 15th, the third day of the TCT event, MGuard(TM)was implanted in a complex PCI procedure broadcasted live from Krakow, Polandto TCT '08 attendees. The procedure was performed by Dr. Dariusz Dudek andmoderated by Dr. Martin Leon. The patient was suffering from an acute MI(heart attack) and initial angiography demonstrated a large thrombusobstructing the right coronary artery. MGuard(TM) was successfully deliveredin an extremely complex procedure involving the use of new imaging techniquesaimed to locate the best site to deploy the stent. When asked about the caseand his experience with the MGuard(TM), Dr. Dudek stated: "We performeddirect stenting on a patient with an acute myocardial infarction and a verylarge thrombotic lesion. We used an MGuardTM stent which covered the entirethrombus, preventing defragmentation and massive embolization. The finalresult was very good with a final TIMI 3 flow and a very good myocardialblush. I think that the MGuardTM stent system helped us to achieve very goodresults in a very difficult set up."
The MGuard(TM) breakfast meeting symposium "A New Approach to TreatingThrombus Containing Lesions (ACS, AMI and SVG)" was a great sensation. Themeeting room was filled to its maximum capacity while additional attendeesstood and listened in the halls outside the room. Dr. Martin Leon chaired themeeting and presented MGuard(TM) solutions for current stenting problems suchas distal macro and micro embolization, axial displacement, persistentintra-luminal narrowing, and increased neointimal hyperplasia. Dr. Abizaidpresented the outstanding interim results of the ongoing Brazil multi-centerGUARD study and Dr. Artur Dziewierz from Dr. Dudek's clinic presentedexcellent preliminary study results from the ongoing MGuard(TM) STEMI MAGICAL(MGuard(TM) in SVG and Native Coronaries) trial in Krakow, Poland. Additionalspeakers and panel members at the meeting included Yaron Almagor MD, ChaimLotan MD, and Carlo Di Mario MD. The panel discussions included the promiseand future potential of MGuardTM carotid and peripheral. At this dynamicmeeting, it was agreed by key opinion leaders from around the world that theMGuard(TM) is feasible for the treatment of thrombus containing lesionsespecially in Acute MI and SVG.
About MGuard(TM) Coronary
The MGuard(TM) Coronary stent presents a novel combination of a coronarystent merged with an embolic protection device. The embolic protection deviceis comprised of an ultra-thin polymer mesh protective sleeve, wrapped aroundthe stent. The protective sleeve is composed of a micron-level-fiber knittednet, engineered in an optimal geometric configuration and designed for utmostflexibility while retaining strength characteristics of the fiber material.The sleeve is designed to expand seamlessly when the stent is deployed,without affecting the structural integrity of the stent, and to preventplaque detachment during and post procedure. The MGuard(TM) Coronary stentprovides long acting embolic protection, without adding complexity duringdelivery. The net is designed to diffuse stent pressure on the vessel walland, thereby may reduce injury and lower the likelihood of restenosis.MGuard(TM) is CE Mark approved.
The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiasticwelcome from leading interventional cardiologists around the world.
InspireMD, Ltd. is an innovative medical device company focusing on thedevelopment and commercialization of its proprietary stent system technology,MGuard(TM). The company intends to apply its technology to develop productsused in interventional cardiology and other vascular procedures. InspireMD'smission is to utilize its proprietary technology to make its products theindustry standard for stents and to provide a superior solution to the keyclinical issues of current stenting procedures: restenosis, embolic showers,and late thrombosis.
In addition to providing embolic protection and minimizing arterialinjury, this promising future technology is aimed at providing an effectiveand uniform drug delivery mechanism with the help of the novel micron-levelnet for next generation drug eluting stents. InspireMD intends to pursueapplications of this technology both for bare metal and drug eluting stentsin coronary, carotid and peripheral artery procedures. For furtherinformation visit http://www.inspire-md.comContact: Jonina Ohayon Marketing Director Tel +972-52-5791120 email@example.com
SOURCE InspireMD, Ltd.
You May Also Like